Lytgobi (futibatinib)
Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh. Oral Tablet
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used to treat a certain type of cancer (bile duct cancer). Futibatinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.
Generic name: futibatinib
Pronunciation: (FUE-ti-BA-ti-nib)
Drug class: Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh.
Therapeutic class: Antineoplastics
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Lytgobi
Indications
The following indications are listed for Lytgobi:
- Cholangiocarcinoma With Fibroblast Growth Factor Receptor 2 (Fgfr2) Fusion Or Other Rearrangement
Also known as: Cca With Fgfr2 Gene Fusion Or Rearrangement.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Lytgobi 12 Mg Dose (3X 4Mg Tb) | Maintenance | Take by oral route once daily per package directions. |
| Lytgobi 16 Mg Dose (4X 4Mg Tb) | Maintenance | Take by oral route once daily per package directions. |
| Lytgobi 20 Mg Dose (5X 4Mg Tb) | Maintenance | Take by oral route once daily per package directions. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Futibatinib/Strong Cyp3a4 Inducers
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Futibatinib is primarily metabolized by CYP3A4. Agents that induce CYP3A4 may reduce the plasma levels of futibatinib.(1)
CLINICAL EFFECTS: Concurrent or recent use of strong CYP3A4 inducers may result in decreased levels and effectiveness of futibatinib.(1)
PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks.
PATIENT MANAGEMENT: The manufacturer of futibatinib states concurrent use with strong CYP3A4 inducers should be avoided.(1)
DISCUSSION: Coadministration with rifampin (strong CYP3A4 inducer) decreased the maximum concentration (Cmax) and area-under-curve (AUC) of futibatinib by 53% and 64%, respectively.(1) Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin, rifapentine, and St. John's wort.(2,3)
Futibatinib/Strong Cyp3a4 Inhibitors
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Futibatinib is primarily metabolized by CYP3A4. Agents that are strong CYP3A4 inhibitors may inhibit the metabolism of futibatinib.(1)
CLINICAL EFFECTS: Concurrent use with inhibitors of CYP3A4 may result in elevated systemic levels and toxicity from futibatinib including hyperphosphatemia, retinal pigment epithelial detachment and elevated liver enzymes.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of futibatinib states concurrent use with strong CYP3A4 inhibitors should be avoided.(1)
DISCUSSION: In an interaction study, multiple doses of itraconazole (an inhibitor of CYP3A4) increased the mean maximum concentration (Cmax) and area-under-curve (AUC) of futibatinib by 51% and 41%, respectively.(1) Strong CYP3A4 inhibitors linked to this monograph include: adagrasib, boceprevir, ceritinib, clarithromycin, cobicistat, ensitrelvir, grapefruit, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, levoketoconazole, lonafarnib, lopinavir, mibefradil, mifepristone, nefazodone, nelfinavir, nirmatrelvir, paritaprevir, posaconazole, relacorilant, ribociclib, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, tucatinib, and voriconazole.(2,3)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Lactation
- Pregnancy
- Hyperphosphatemia
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Anemia
- Hypercalcemia
- Hyperphosphatemia
- Hyponatremia
- Lymphopenia
Less Frequent
- Ascites
- Biliary obstruction
- Gastrointestinal hemorrhage
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Neutropenic disorder
- Retinal pigment epithelial detachment
- Thrombocytopenic disorder
Rare or Very Rare
- Calcification of vascular system
- Calcinosis cutis
- Calciphylaxis
More Frequent
- Acute abdominal pain
- Alopecia
- Anorexia
- Arthralgia
- Constipation
- Diarrhea
- Dry eye
- Dry skin
- Dysgeusia
- Fatigue
- Hyperglycemia
- Musculoskeletal pain
- Nail disorders
- Nausea
- Palmar-plantar erythrodysesthesia
- Stomatitis
- Urinary tract infection
- Vomiting
- Xerostomia
Less Frequent
- Fever
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFr2) fusion or other rearrangement | ||
| C22.1 | ICD10CM | Intrahepatic bile duct carcinoma |
| C24.0 | ICD10CM | Malignant neoplasm of extrahepatic bile duct |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.